Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;57(7):3445-9.
doi: 10.1128/AAC.00388-13. Epub 2013 May 6.

Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Kwok-Chiu Chang  1 , Wing-Wai Yew, Siu-Wai Cheung, Chi-Chiu Leung, Cheuk-Ming Tam, Chi-Hung Chau, Peter Kin-Ho Wen, Raphael Chiu-Yeung Chan
Affiliations

Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Kwok-Chiu Chang et al. Antimicrob Agents Chemother. 2013 Jul.

Abstract

We evaluated treatment with linezolid, dosed at 800 mg once daily for 1 to 4 months as guided by sputum culture status and tolerance and then at 1,200 mg thrice weekly until ≥ 1 year after culture conversion, in addition to individually optimized regimens among 10 consecutive patients with extensively drug-resistant tuberculosis or fluoroquinolone-resistant multidrug-resistant tuberculosis. All achieved stable cure, with anemia corrected and neuropathy stabilized, ameliorated, or avoided after switching to intermittent dosing. Serum linezolid profiles appeared better optimized.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Serum pharmacokinetics of oral linezolid at 1,200 mg thrice weekly.
Fig 2
Fig 2
Serum pharmacokinetics of oral linezolid at 600 mg thrice weekly.
Fig 3
Fig 3
Serum pharmacokinetics of oral linezolid at 600 mg once daily.
See this image and copyright information in PMC

References

    1. World Health Organization 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. World Health Organization, Geneva, Switzerland: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf
    1. Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB. 2012. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J. 40:1430–1442 - PubMed
    1. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ. 2002. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 46:2723–2726 - PMC - PubMed
    1. Bressler AM, Zimmer SM, Gilmore JL, Somani J. 2004. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. 4:528–531 - PubMed
    1. Koh W-J, Kwon OJ, Gwak H, Chung JW, Cho S-N, Kim WS, Shim TS. 2009. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J. Antimicrob. Chemother. 64:388–391 - PubMed

Publication types

LinkOut - more resources